The Wisconsin startup company, Pantherics Incorporated, merged last month with San Diego based Bio33 Degrees, Inc., creating a unified drug discovery and development platform to target GABAAR in peripheral tissues. Lead therapeutic programs address unmet needs in asthma and atopic dermatitis treatment. The newly formed company also combines the extensive experience in discovery science, drug development, organizational development, and strategic finance of the company founders – Drs. Stafford and Arnold and Mr. Peterson from Pantherics and Drs. Dobak and Piacquadio from Bio33. The new company retains the Pantherics Incorporated name and has business locations in both Wisconsin and California. Our team recently published two more journal articles, describing: 1) rapid bronchodilation in mice treated with nebulized asthma lead drug MIDD0301 (Yocum, et al. 2018 Am. J. Physiol. Lung Cell Mol. Physiol.) and 2) a four week immunotoxicity study of MIDD0301 showing no systemic humoral immune suppression and no adverse effects on weight, hematology, or immune organ morphology (Zahn, et al. 2019 Basic & Clinical Pharmacology & Toxicology).
Milwaukee, WI, March 20, 2019